Literature DB >> 26617887

Multidrug resistance protein and topoisomerase 2 alpha expression in non-small cell lung cancer are related with brain metastasis postoperatively.

Huan Huang1, Jihong Liu2, Qinglian Meng1, Guozhong Niu1.   

Abstract

The aim of this study was to investigate association between expressions of multidrug resistance protein (MRP) and topoisomerase 2 alpha expression in non-small cell lung cancer (TOP2A) and brain metastasis operatively. The expression of MRP and TOP2A were performed using immunohistochemistry (IHC) staining, and the results were analyzed in correlation with clinicopathological data. A total of 286 NSCLC patients who underwent curative surgery between 2007 and 2013 were enrolled in this study. Positive expression of MRP and TOP2A were 62.2% and 37.8%. MRP positive expression in NSCLC was significantly correlated with tumor cell differentiation (P=0.028). TOP2A expression was significantly associated with patients' smoking status, tumor histological type (P<0.05). The positive MRP group had significantly inferior survival rates for 2-year BMFS than did the negative MRP group (79.0% vs. 93.4%, P=0.003) by the Kaplan-Meier method and a log-rank test. Similarly, the positive TOP2A expression was inversely correlated with 2-year BMFS (84.2% vs. 93.4%, P=0.030). Multivariate analysis showed that gender, MRP expression and TOP2A expression were independent prognostic factors for BMFS (P<0.05). Positive expressions of MRP and TOP2A in the tumor tissue are associated with increased risk of developing brain metastases in NSCLC.

Entities:  

Keywords:  Multidrug resistance protein; brain metastasis; non-small cell lung cancer; topoisomerase 2 alpha

Mesh:

Substances:

Year:  2015        PMID: 26617887      PMCID: PMC4637703     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  19 in total

1.  A nomogram to predict brain metastasis as the first relapse in curatively resected non-small cell lung cancer patients.

Authors:  Young-Woong Won; Jungnam Joo; Tak Yun; Geon-Kook Lee; Ji-Youn Han; Heung Tae Kim; Jin Soo Lee; Moon Soo Kim; Jong Mog Lee; Hyun-Sung Lee; Jae Ill Zo; Sohee Kim
Journal:  Lung Cancer       Date:  2015-02-16       Impact factor: 5.705

Review 2.  Topoisomerase IIα, rather than IIβ, is a promising target in development of anti-cancer drugs.

Authors:  W Chen; J Qiu; Y M Shen
Journal:  Drug Discov Ther       Date:  2012-10

3.  Prognostic factors for patients in postoperative brain metastases from surgically resected non-small cell lung cancer.

Authors:  Jin Sakamoto; Makoto Sonobe; Masashi Kobayashi; Masashi Ishikawa; Ryutaro Kikuchi; Daisuke Nakajima; Tetsu Yamada; Ei Nakayama; Tsuyoshi Takahashi; Toshihiko Sato; Fengshi Chen; Toru Bando; Hiroshi Date
Journal:  Int J Clin Oncol       Date:  2012-12-14       Impact factor: 3.402

4.  Expression of P-gp, MRP, LRP, GST-π and TopoIIα and intrinsic resistance in human lung cancer cell lines.

Authors:  Jiarui Wang; Jinhui Zhang; Lichuan Zhang; Long Zhao; Sufang Fan; Zhonghai Yang; Fei Gao; Ying Kong; Gary Guishan Xiao; Qi Wang
Journal:  Oncol Rep       Date:  2011-07-28       Impact factor: 3.906

5.  Overexpression of adenylate cyclase-associated protein 1 may predict brain metastasis in non-small cell lung cancer.

Authors:  Shuan-Shuan Xie; Min Tan; Hai-Yan Lin; Lei Xu; Chang-Xing Shen; Qing Yuan; Xiao-Lian Song; Chang-Hui Wang
Journal:  Oncol Rep       Date:  2014-10-30       Impact factor: 3.906

6.  Surgical treatment of primary lung cancer with synchronous brain metastases.

Authors:  P S Billing; D L Miller; M S Allen; C Deschamps; V F Trastek; P C Pairolero
Journal:  J Thorac Cardiovasc Surg       Date:  2001-09       Impact factor: 5.209

7.  Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: prognostic implications.

Authors:  Walter Berger; Ulrike Setinek; Peter Hollaus; Thomas Zidek; Elisabeth Steiner; L Elbling; H Cantonati; Johannes Attems; Andrea Gsur; Michael Micksche
Journal:  J Cancer Res Clin Oncol       Date:  2005-01-27       Impact factor: 4.553

8.  Who may benefit from prophylactic cranial irradiation amongst stage III non-small cell lung cancer patients?

Authors:  I Alsan Cetin; Z Akgun; Beste M Atasoy; P Fulden Yumuk; U Abacioglu
Journal:  J BUON       Date:  2013 Apr-Jun       Impact factor: 2.533

9.  The role of multidrug resistance-associated protein in the blood-brain barrier and opioid analgesia.

Authors:  Wendy Su; Gavril W Pasternak
Journal:  Synapse       Date:  2013-05-02       Impact factor: 2.562

10.  Brain metastases admissions in Sweden between 1987 and 2006.

Authors:  K E Smedby; L Brandt; M L Bäcklund; P Blomqvist
Journal:  Br J Cancer       Date:  2009-10-13       Impact factor: 7.640

View more
  14 in total

1.  Robust network-based regularization and variable selection for high-dimensional genomic data in cancer prognosis.

Authors:  Jie Ren; Yinhao Du; Shaoyu Li; Shuangge Ma; Yu Jiang; Cen Wu
Journal:  Genet Epidemiol       Date:  2019-02-11       Impact factor: 2.135

2.  Tumor profiling of co-regulated receptor tyrosine kinase and chemoresistant genes reveal different targeting options for lung and gastroesophageal cancers.

Authors:  Jianzhong Wu; Shuchun Li; Rong Ma; Ashok Sharma; Shan Bai; Boying Dun; Haixia Cao; Changwen Jing; Jinxiong She; Jifeng Feng
Journal:  Am J Transl Res       Date:  2016-12-15       Impact factor: 4.060

3.  The microRNA expression signature of small cell lung cancer: tumor suppressors of miR-27a-5p and miR-34b-3p and their targeted oncogenes.

Authors:  Keiko Mizuno; Hiroko Mataki; Takayuki Arai; Atsushi Okato; Kazuto Kamikawaji; Tomohiro Kumamoto; Tsubasa Hiraki; Kazuhito Hatanaka; Hiromasa Inoue; Naohiko Seki
Journal:  J Hum Genet       Date:  2017-03-09       Impact factor: 3.172

4.  The CK2 inhibitor CX4945 reverses cisplatin resistance in the A549/DDP human lung adenocarcinoma cell line.

Authors:  Chengji Jin; Ping Song; Ji Pang
Journal:  Oncol Lett       Date:  2019-08-01       Impact factor: 2.967

5.  Temporin A and Bombinin H2 Antimicrobial Peptides Exhibit Selective Cytotoxicity to Lung Cancer Cells.

Authors:  Lucy Swithenbank; Phillipa Cox; Llinos G Harris; Edward Dudley; Kathryn Sinclair; Paul Lewis; Floriana Cappiello; Claire Morgan
Journal:  Scientifica (Cairo)       Date:  2020-06-26

6.  Mining expression and prognosis of topoisomerase isoforms in non-small-cell lung cancer by using Oncomine and Kaplan-Meier plotter.

Authors:  Guo-Xin Hou; Panpan Liu; Jing Yang; Shijun Wen
Journal:  PLoS One       Date:  2017-03-29       Impact factor: 3.240

7.  Meta-analysis of whole-brain radiotherapy plus temozolomide compared with whole-brain radiotherapy for the treatment of brain metastases from non-small-cell lung cancer.

Authors:  Yong Xin; WenWen Guo; Chun Sheng Yang; Qian Huang; Pei Zhang; Long Zhen Zhang; Guan Jiang
Journal:  Cancer Med       Date:  2018-03-07       Impact factor: 4.452

8.  Profiles of brain metastases: Prioritization of therapeutic targets.

Authors:  Sherise D Ferguson; Siyuan Zheng; Joanne Xiu; Shouhao Zhou; Mustafa Khasraw; Priscilla K Brastianos; Santosh Kesari; Jethro Hu; Jeremy Rudnick; Michael E Salacz; David Piccioni; Suyun Huang; Michael A Davies; Isabella C Glitza; John V Heymach; Jianjun Zhang; Nuhad K Ibrahim; John F DeGroot; Joseph McCarty; Barbara J O'Brien; Raymond Sawaya; Roeland G W Verhaak; Sandeep K Reddy; Waldemar Priebe; Zoran Gatalica; David Spetzler; Amy B Heimberger
Journal:  Int J Cancer       Date:  2018-10-09       Impact factor: 7.396

9.  Identification and validation of NOLC1 as a potential target for enhancing sensitivity in multidrug resistant non-small cell lung cancer cells.

Authors:  Huaping Huang; Tangying Li; Mingjing Chen; Feng Liu; Haifeng Wu; Jie Wang; Jialiang Chen; Xi Li
Journal:  Cell Mol Biol Lett       Date:  2018-11-27       Impact factor: 5.787

10.  Quantifying critical states of complex diseases using single-sample dynamic network biomarkers.

Authors:  Xiaoping Liu; Xiao Chang; Rui Liu; Xiangtian Yu; Luonan Chen; Kazuyuki Aihara
Journal:  PLoS Comput Biol       Date:  2017-07-05       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.